Nicotinamide-adenine-dinucleotide-5-hydroxy-4-oxonorvaline

Star0

DB02349ExperimentalSmall molecule

Nicotinamide-adenine-dinucleotide-5-hydroxy-4-oxonorvaline: Overview.

Formula / weight: C₂₆H₃₅N₈O₁₈P₂ · 809.5464 g/mol (avg)

Resolves to

Compound

PubChem5289029

Structure

InChIKeyRSVNLFPFYXGAGU-GIBQRGJUSA-OSMILES

[H]N([H])[C@@H](CC(=O)[C@@H](O)C1=C(C=[N+](C=C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N=CN=C23)N([H])[H])[C@@H](O)[C@H]1O)C(=O)N([H])[H])C(O)=O

Which companies are running trials of Nicotinamide-adenine-dinucleotide-5-hydroxy-4-oxonorvaline, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account